

AMENDMENTS TO THE SPECIFICATION:

Please amend the specification as shown:

Please delete the paragraph on page 9, lines 13-33 and replace it with the following paragraph:

The present invention also relates to a molecule as defined above, characterized in that -D and -D' represent residues derived from the human or murine CD40 receptor ligand (CD40L), chosen from the following:

Lys¹⁴³-Gly-Tyr¹⁴⁵ (SEQ ID NO: 1), Tyr¹⁴⁵-Gly-Lys¹⁴³ (SEQ ID NO: 2),

Lys¹⁴³-Gly-Tyr-Tyr¹⁴⁶ (SEQ ID NO: 3), Tyr¹⁴⁶-Tyr-Gly-Lys¹⁴³ (SEQ ID NO: 4),

Lys-Pro-Arg (SEQ ID NO: 5), Lys-ψ(CH₂NH)Pro-Arg (SEQ ID NO: 24),

Arg²⁰⁰-Phe-Glu-Arg-Ile-Leu-Leu-Arg²⁰⁷ (SEQ ID NO: 6),

Arg²⁰⁷-Leu-Leu-Ile-Arg-Glu-Phe-Arg²⁰⁰ (SEQ ID NO: 7),

Arg²⁰⁰-Phe-Glu-Arg-Ile²⁰⁴ (SEQ ID NO: 25),

Ile²⁰⁴-Arg-Glu-Phe-Arg²⁰⁰ (SEQ ID NO: 9),

Arg²⁰³-Ile-Leu-Leu-Arg²⁰⁷ (SEQ ID NO: 10),

Arg²⁰⁷-Leu-Leu-Ile-Arg²⁰³ (SEQ ID NO: 11),

Cys²¹⁸-Gly-Gln-Gln-Ser-Ile²²³ (SEQ ID NO: 12),

Ile²²³-Ser-Gln-Gln-Gly-Cys²¹⁸ (SEQ ID NO: 26),

Gly²⁰⁰-Ser-Glu-Arg-Ile-Leu-Leu-Lys²⁰⁷ (SEQ ID NO: 14),

Lys²⁰⁷-Leu-Leu-Ile-Arg-Glu-Ser-Gly²⁰⁰ (SEQ ID NO: 15),

Gly²⁰⁰-Ser-Glu-Arg-Ile²⁰⁴ (SEQ ID NO: 16),

Ile²⁰⁴-Arg-Glu-Ser-Gly²⁰⁰ (SEQ ID NO: 17),
Arg²⁰³-Ile-Leu-Leu-Lys²⁰⁷ (SEQ ID NO: 18),
Lys²⁰⁷-Leu-Leu-Ile-Arg²⁰³ (SEQ ID NO: 19),
Cys²¹⁸-Glu-Gln-Gln-Ser-Val²²³ (SEQ ID NO: 20),
Val²²³-Ser-Gln-Gln-Glu-Cys²¹⁸ (SEQ ID NO: 21),
or from hybrid peptides constituted by at least two
consecutive amino acids of two of the sequences
defined above, in particular the peptides of sequences
Arg²⁰³-Ile²⁰⁴-Tyr¹⁴⁵-Tyr¹⁴⁶ (SEQ ID NO: 22) or Arg²⁰³-
Ile²⁰⁴-Tyr¹⁴⁶-Tyr¹⁴⁵-Gly¹⁴⁴-Lys¹⁴³ (SEQ ID NO: 23),
or from fragments of the abovementioned sequences,
the amino acids being equally able to be of L or D
configuration.

Please delete the paragraph on page 10, lines 19-20 and replace it
with the following paragraph:

An advantageous molecule of the present invention is a
molecule as defined above, of the following formula (peptide
sequences KGYG and YYGK disclosed as SEQ ID NOS 3 and 4,
respectively):

Please delete the paragraph on page 22, line 21 and replace it
with the following paragraph:

Compound L3 corresponds to the following formula (peptide sequence
KGYG disclosed as SEQ ID NO: 3):

Please delete the paragraph on page 23, line 8 and replace it with the following paragraph:

Compound L4 corresponds to the following formula (peptide sequence KGYG disclosed as SEQ ID NO: 3):

Please delete the paragraph on page 23, line 21 and replace it with the following paragraph:


Compound L4a corresponds to the following formula (peptide sequence KGYG disclosed as SEQ ID NO: 3):

Please delete the paragraph on page 29, line 21 and replace it with the following paragraph:


The reactions on resins were carried out in a syringe under stirring (peptide sequence KGYG disclosed as SEQ ID NO: 3).

Please delete the paragraph on page 32, lines 3-20 and replace it with the following paragraph:


It is the acetylated sequence: Ac-Lys-Gly-Tyr-Tyr- (SEQ ID NO: 3) which will produce the construction L7-1 (peptide sequence KGYG disclosed as SEQ ID NO: 3)



and the reverse sequence: H-Tyr-Tyr-Gly-Lys- (SEQ ID NO: 4) which will produce the construction **L7-2** (peptide sequence YYGK disclosed as SEQ ID NO: 4)



or modification of the spacer arm: replacement of the aminohexanoic acid by a glycine: **L7-3** (peptide sequence KGYY disclosed as SEQ ID NO: 3)



L-7-3

Please delete the paragraph on page 32, line 26 and replace it with the following paragraph:

The ligand L11 corresponds to the following formula (peptide sequences KGYG and K(Boc)-G-Y(tBu)-Y(tBu) disclosed as SEQ ID NOS 3 and 27, respectively):

Please delete the paragraph on page 39, line 4 and replace it with the following paragraph:

Reaction diagram (peptide sequence KGYG disclosed as SEQ ID NO: 3):

Please delete the paragraph on page 40, line 10 and replace it with the following paragraph:

H) PREPARATION OF L12 (peptide sequence KGYG disclosed as SEQ ID NO: 3):